-
Something wrong with this record ?
Stem Cell Transcription Factor Sox2 Is Expressed in a Subset of Folliculo-stellate Cells of Growth Hormone-Producing Pituitary Neuroendocrine Tumours and Its Expression Shows No Association with Tumour Size or IGF1 Levels: a Clinicopathological Study of 109 Cases
J. Soukup, T. Česák, H. Hornychová, K. Michalová, Ľ. Michnová, D. Netuka, J. Čáp, F. Gabalec
Language English Country United States
Document type Journal Article
Grant support
NV19-01-00435
Ministerstvo Zdravotnictví Ceské Republiky
NLK
ProQuest Central
from 1997-04-01 to 1 year ago
Medline Complete (EBSCOhost)
from 1997-03-01 to 1 year ago
Health & Medicine (ProQuest)
from 1997-04-01 to 1 year ago
- MeSH
- Acromegaly etiology metabolism MeSH
- Adult MeSH
- Insulin-Like Growth Factor I metabolism MeSH
- Stem Cells metabolism MeSH
- Middle Aged MeSH
- Humans MeSH
- Human Growth Hormone metabolism MeSH
- Biomarkers, Tumor metabolism MeSH
- Pituitary Neoplasms complications pathology MeSH
- Neuroendocrine Tumors complications pathology MeSH
- SOXB1 Transcription Factors metabolism MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
Sox2 is one of the transcription factors responsible for the maintenance of stem cell phenotype. It has been implicated as a marker of stem cells in normal pituitaries and pituitary neuroendocrine tumours. To explore the clinical significance of Sox2 expression in histological sections, we performed immunohistochemical detection of Sox2 in 113 pituitary neuroendocrine tumours from 109 patients with acromegaly. In 11 tumours, we performed double immunostaining for Sox2, annexin A1 and S100 protein. Tumours were characterised using the WHO classification system. Proliferative activity and invasion were assessed. The amount of immunoreactive cells was evaluated and correlated with tumour size and biochemical features (levels of IGF1, GH, prolactin, βTSH). Sox2+ cells were identified in 35/38 normal pituitaries adjacent to the tumours. In 36 tumours (33%), ≥ 1% of the cells expressed Sox2, in 24 cases (22%), Sox2+ cells comprised < 1% and 49 cases (45%) were negative. We found no significant differences between Sox2+ and Sox2- groups with respect to the age, initial levels of GH, IGF1, prolactin, βTSH, tumour size, invasion, proliferative activity or histological features. We observed a positive correlation between Sox2+ cell count and βTSH immunoreactive cells (r = 0.459, p < 0.001) that was further verified by multivariate analysis. Using double stain, the majority of Sox2+ cells coexpressed annexin A1 (average 89%) and S100 protein (average 76.2%) and showed morphological features of folliculo-stellate cells. Sox2+ cells are thus commonly present in growth hormone-producing tumours and normal pituitaries, and their amount does not have any prognostic significance. Most of these cells represent a subpopulation of folliculo-stellate cells, pointing out to their role as a possible stem cell population.
Bioptical Laboratory Ltd Plzen Czech Republic
Department of Pathology Faculty of Medicine in Plzen Charles University Plzen Czech Republic
Department of Pathology Military University Hospital Prague Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026370
- 003
- CZ-PrNML
- 005
- 20211026132945.0
- 007
- ta
- 008
- 211013s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12022-020-09634-1 $2 doi
- 035 __
- $a (PubMed)32632839
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Soukup, Jiri $u The Fingerland Department of Pathology, University Hospital and Faculty of Medicine Hradec Kralove, Charles University, Sokolska 581, 500 05, Hradec Kralove, Czech Republic. 2jiri.soukup@gmail.com
- 245 10
- $a Stem Cell Transcription Factor Sox2 Is Expressed in a Subset of Folliculo-stellate Cells of Growth Hormone-Producing Pituitary Neuroendocrine Tumours and Its Expression Shows No Association with Tumour Size or IGF1 Levels: a Clinicopathological Study of 109 Cases / $c J. Soukup, T. Česák, H. Hornychová, K. Michalová, Ľ. Michnová, D. Netuka, J. Čáp, F. Gabalec
- 520 9_
- $a Sox2 is one of the transcription factors responsible for the maintenance of stem cell phenotype. It has been implicated as a marker of stem cells in normal pituitaries and pituitary neuroendocrine tumours. To explore the clinical significance of Sox2 expression in histological sections, we performed immunohistochemical detection of Sox2 in 113 pituitary neuroendocrine tumours from 109 patients with acromegaly. In 11 tumours, we performed double immunostaining for Sox2, annexin A1 and S100 protein. Tumours were characterised using the WHO classification system. Proliferative activity and invasion were assessed. The amount of immunoreactive cells was evaluated and correlated with tumour size and biochemical features (levels of IGF1, GH, prolactin, βTSH). Sox2+ cells were identified in 35/38 normal pituitaries adjacent to the tumours. In 36 tumours (33%), ≥ 1% of the cells expressed Sox2, in 24 cases (22%), Sox2+ cells comprised < 1% and 49 cases (45%) were negative. We found no significant differences between Sox2+ and Sox2- groups with respect to the age, initial levels of GH, IGF1, prolactin, βTSH, tumour size, invasion, proliferative activity or histological features. We observed a positive correlation between Sox2+ cell count and βTSH immunoreactive cells (r = 0.459, p < 0.001) that was further verified by multivariate analysis. Using double stain, the majority of Sox2+ cells coexpressed annexin A1 (average 89%) and S100 protein (average 76.2%) and showed morphological features of folliculo-stellate cells. Sox2+ cells are thus commonly present in growth hormone-producing tumours and normal pituitaries, and their amount does not have any prognostic significance. Most of these cells represent a subpopulation of folliculo-stellate cells, pointing out to their role as a possible stem cell population.
- 650 _2
- $a akromegalie $x etiologie $x metabolismus $7 D000172
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a nádorové biomarkery $x metabolismus $7 D014408
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidský růstový hormon $x metabolismus $7 D019382
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a insulinu podobný růstový faktor I $x metabolismus $7 D007334
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a neuroendokrinní nádory $x komplikace $x patologie $7 D018358
- 650 _2
- $a nádory hypofýzy $x komplikace $x patologie $7 D010911
- 650 _2
- $a transkripční faktory SOXB1 $x metabolismus $7 D055748
- 650 _2
- $a kmenové buňky $x metabolismus $7 D013234
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Česák, Tomáš $u Department of Neurosurgery, University Hospital and Faculty of Medicine Hradec Kralove, Charles University, Sokolska 581, 500 05, Hradec Kralove, Czech Republic
- 700 1_
- $a Hornychová, Helena $u The Fingerland Department of Pathology, University Hospital and Faculty of Medicine Hradec Kralove, Charles University, Sokolska 581, 500 05, Hradec Kralove, Czech Republic
- 700 1_
- $a Michalová, Květoslava $u Department of Pathology, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic $u Bioptical Laboratory, Ltd., Plzen, Czech Republic
- 700 1_
- $a Michnová, Ľudmila $u Department of Pathology, Military University Hospital Prague, Prague, Czech Republic
- 700 1_
- $a Netuka, David $u Department of Neurosurgery and Neurooncology, 1st Medical Faculty, Charles University, Military University Hospital Prague, Prague, Czech Republic
- 700 1_
- $a Čáp, Jan $u 4th Department of Internal Medicine, University Hospital and Faculty of Medicine Hradec Kralove, Charles University, Sokolska 581, 500 05, Hradec Kralove, Czech Republic
- 700 1_
- $a Gabalec, Filip $u 4th Department of Internal Medicine, University Hospital and Faculty of Medicine Hradec Kralove, Charles University, Sokolska 581, 500 05, Hradec Kralove, Czech Republic
- 773 0_
- $w MED00001517 $t Endocrine pathology $x 1559-0097 $g Roč. 31, č. 4 (2020), s. 337-347
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32632839 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026132951 $b ABA008
- 999 __
- $a ok $b bmc $g 1715170 $s 1146877
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 31 $c 4 $d 337-347 $e - $i 1559-0097 $m Endocrine pathology $n Endocr Pathol $x MED00001517
- GRA __
- $a NV19-01-00435 $p Ministerstvo Zdravotnictví Ceské Republiky
- LZP __
- $a Pubmed-20211013